BTIG reiterates Buy on Rapport Therapeutics, lifts $75 target
BTIG maintained a Buy rating on Rapport Therapeutics with a $75.00 price target, implying 75.7% upside versus the Sep 15 close of $42.68.
Story updates
10:33:57 AM UTC
SquawkNews
Ratings actions GMT) Rapport Therapeutics Is Maintained at Buy by BTIGRatings actions
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.